Skip to main content
TipRanks
Go Ultimate75% OFF

Viemed Healthcare (VMD) AI Stock Analysis

182 Followers
VMD

Viemed Healthcare

(NASDAQ:VMD)

Select Model
Rating:65Neutral
Price Target:$11.00â–²(19.96% Upside)
Action:reiterated
Date:11/06/26

Viemed Healthcare's overall score of 65 reflects a company with a strong financial foundation and positive operational momentum, offset by profitability and cash flow challenges. The most significant positive factors are the fortress-like balance sheet and the constructive earnings call, which highlighted record revenue, raised guidance, and clear growth catalysts in sleep and maternal health. Technical trends are also supportive. However, these strengths are weighed down by a weak cash flow profile, compressing margins, and a dramatic slowdown in revenue growth, which introduce financial risk. The moderate P/E ratio and lack of a dividend further temper the overall score.

Positive Factors
Sustained Revenue GrowthViemed has delivered sustained top-line expansion across several years, reaching $310.4 million in TTM revenue. This indicates growing adoption of its home-based care model and provides a durable base for further scale, investment, and earnings growth.
Negative Factors
Margin CompressionAlthough revenue is growing quickly, lower operating and EBITDA margins show that earnings are not expanding as efficiently as sales. If this pattern persists, Viemed may need continued volume growth to offset weaker profitability and preserve earnings momentum.

Viemed Healthcare (VMD) vs. SPDR S&P 500 ETF (SPY)

-20%0%20%40%60%80%100%VMD+45.32%SPY+14.55%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$347.48M
Dividend Yield
―
Average Volume (3M)
273.48K
Price to Earnings (P/E)
22.5
Beta (1Y)
0.47
Revenue Growth
21.81%
EPS Growth
17.67%
Country
US
Employees
1,490
Sector
Healthcare
Sector Strength
51
Industry
Medical - Care Facilities

Viemed Healthcare Business Overview & Revenue Model

Company Description

Viemed Healthcare, Inc., through its subsidiaries, provides home medical equipment (HME) and post-acute respiratory healthcare services in the United States. The company provides respiratory disease management solutions, including treatment of chroni...

How the Company Makes Money

Viemed primarily makes money by providing home-based respiratory therapy solutions that combine durable medical equipment (DME) with ongoing clinical and support services, and then billing third-party payors for those products and services. Its core...

Viemed Healthcare Earnings Call Summary

Earnings Call Date:Nov 04, 2026(Q3-2026)|% Change Since:-9.30%|Next Earnings Date:Mar 10, 2027
Earnings Call SentimentPositive

The call was broadly positive, led by record revenue, double-digit organic growth, strong net income and adjusted EBITDA expansion, growing sleep and maternal health volumes, improving ventilation revenue, capital returns, and higher revenue guidance. The primary challenges were slightly lower gross margin, increased audit-related work and payment timing, temporarily weaker cash conversion, volatility in ventilation active patients, and a lower upper end to adjusted EBITDA guidance.

Positive Updates

Record Revenue and Strong Net Income Growth
Third-quarter revenue reached a record $80.7 million, up 12.2% year over year. Net income attributable to Viemed increased 32% year over year to $4.6 million, or $0.11 per diluted share, and rose approximately 68% from the second quarter.

Negative Updates

Gross Margin Declined Slightly
Gross profit was $46.2 million, or 57.3% of revenue, compared with 57.5% a year ago and 57.7% in the second quarter. Management attributed the year-over-year margin effect to the shift toward equipment and supply sales, which generally carry lower margins than equipment rentals.

Company Guidance

Management now expects full-year revenue of $316 million to $320 million, compared with the previous range of $314 million to $320 million; adjusted EBITDA guidance is $64 million to $66 million, compared with the previous range of $64 million to $68 million; and net CapEx is expected to be 8% to 9% of revenue, compared with 8.5% to 10% previously. The revised outlook anticipates sequential growth in both revenue and adjusted EBITDA in the fourth quarter and excludes any potential future acquisitions or strategic transactions. Viemed is on track to enter 2 additional states per quarter beginning in the fourth quarter for maternal health, expects ventilator active patient count to be back up in the fourth quarter, and expects to stay up in the 20-plus percent adjusted EBITDA for the time being.

Viemed Healthcare Financial Statement Overview

Summary

Financial performance is mixed. The balance sheet is a key strength with very low debt (D/E 0.06) and a healthy ROE of 10.3%. However, this is offset by deteriorating income trends, including a sharp revenue growth deceleration to 2.9% TTM and compressing net margins to 5.0%. Cash flow is a significant weakness, with volatile and declining free cash flow, indicating poor conversion of profits.

Income Statement

62Positive

Balance Sheet

78Positive

Cash Flow

45Neutral
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue310.37M270.28M224.26M183.01M138.83M117.06M
Gross Profit177.39M155.46M133.20M112.78M84.68M73.41M
EBITDA47.79M51.56M42.31M36.68M24.82M24.13M
Net Income15.62M14.93M11.27M10.24M6.22M9.13M
Balance Sheet
Total Assets207.63M199.15M177.07M154.90M117.04M117.96M
Cash, Cash Equivalents and Short-Term Investments9.68M13.50M17.54M12.84M16.91M28.41M
Total Debt9.28M15.95M6.87M10.32M694.00K6.52M
Total Liabilities55.65M55.63M43.77M41.00M19.95M23.14M
Stockholders Equity150.09M141.54M131.39M113.89M97.09M94.82M
Cash Flow
Free Cash Flow21.38M11.93M1.32M19.12M4.85M2.75M
Operating Cash Flow53.90M51.92M39.09M45.21M27.75M22.49M
Investing Cash Flow-28.40M-50.17M-30.70M-52.11M-23.98M-19.75M
Financing Cash Flow-26.95M-5.79M-3.69M2.83M-15.27M-5.32M

Viemed Healthcare Technical Analysis

Technical Analysis SentimentNegative
Last Price9.17

Price Trends

50DMA9.28Negative
100DMA9.96Negative
200DMA9.66Negative

Market Momentum

MACD-0.10Positive
RSI45.41Neutral
STOCH29.43Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VMD, the sentiment is Negative. The current price of 9.17 is below the 20-day moving average (MA) of 9.52, below the 50-day MA of 9.28, and below the 200-day MA of 9.66, indicating a bearish trend. The MACD of -0.10 indicates Positive momentum. The RSI at 45.41 is Neutral, neither overbought nor oversold. The STOCH value of 29.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VMD.

Viemed Healthcare Risk Analysis

Viemed Healthcare disclosed 39 risk factors in its most recent earnings report. Viemed Healthcare reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.We cannot guarantee that we will repurchase our common shares pursuant to our share repurchase program or that our share repurchase program will enhance long-term shareholder value. Share repurchases could also increase the volatility of the price of our common shares and could diminish our cash reserves.Q4, 2025
2.CMS actions to impose temporary enrollment moratoria and heightened screening for certain DMEPOS supplier types could limit our ability to expand, pursue acquisitions, or maintain expected operational flexibility and could increase our compliance costs.Q4, 2025
3.A reduction or elimination of coverage or reimbursement of our products by third-party payors, including Medicare, in the future could adversely affect our business and results of operations.Q4, 2025

Viemed Healthcare Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

VMD against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
TCMDTCMD75Outperform$600.58M25.5310.73%―14.41%34.35%
BVSBVS66Neutral$898.22M12.6027.23%―3.87%623.68%
VMDVMD65Neutral$347.48M22.5210.78%―21.81%17.67%
OMOM55Neutral$70.32M-0.96-68.03%―1.58%70.22%
INGNINGN52Neutral$147.95M-4.34-20.06%―-2.28%-31.45%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SENSSENS50Neutral$579.58M-4.52-186.15%―104.83%-37.15%

* Healthcare Sector Average

Performance Comparison

0%50%100%VMDINGNSENSTCMDOMBVSDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
VMD and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
VMDViemed Healthcare US9.172.8845.79%
INGNInogen Inc5.69-1.02-15.20%
SENSSenseonics Holdings Inc.10.584.6879.32%
TCMDTactile Systems Technology26.813.3714.38%
OMOutset Medical, Inc.3.73-1.19-24.19%
BVSBioventus, Inc.10.663.6050.99%

Viemed Healthcare Corporate Events

Stock BuybackFinancial Disclosures

Viemed Reports Record Third-Quarter Revenue and Profit Growth

Positive
Nov 4, 2026

On November 4, 2026, Viemed reported record third-quarter net revenue of $80.7 million, up 12.2% year over year and 3.3% sequentially. Net income attributable to Viemed rose 32.0% year over year to $4.6 million, while Adjusted EBITDA increased 5.8% t...

Business Operations and StrategyRegulatory Filings and Compliance

Viemed Healthcare Updates Investor Deck, Highlights Growth Strategy

Positive
Aug 20, 2026

Viemed Healthcare has released an updated investor deck dated August 2026, which it plans to use in presentations to investors, analysts and other stakeholders, and has made the materials available on its website. The presentation, framed as summary...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 05, 2026